WHO第 技术报告 药物生产技术转移指南 中英文.docx

1、WHO第 技术报告 药物生产技术转移指南 中英文WHO第961号技术报告 附件7 药物生产技术转移指南World Health OrganizationWHO Technical Report Series, No. 961, 2011WHO第961号技术报告 附件7 药物生产技术转移指南Annex 7附件7WHO guidelines on transfer of technology in pharmaceutical manufacturingWHO药物生产技术转移指南1. Introduction介绍2. Scope范围3. Glossary术语4. Organization and

2、management组织和管理5. Production: transfer (processing, packaging and cleaning)生产：转移（工艺、包装和清洁）6. Quality control: analytical method transfer质量控制：分析方法转移7. Premises and equipment厂房设施和设备8. Documentation文件9. Qualification and validation确认和验证References参考文献1.Introduction介绍These guiding principles on transfer

3、of technology are intended to serve as a framework which can be applied in a flexible manner rather than as strict rigid guidance. Focus has been placed on the quality aspects, in line with WHOs mandate.本指南中关于技术转移的原则意在作为一个框架，以不同方式应用，而不是一个需要严格遵守的指南。指南重点在于质量方面，与WHO的任务一致。 Transfer of processes to an al

4、ternative site occurs at some stage in the life-cycle of most products, from development, scale-up, manufacturing, production and launch, to the post-approval phase.将工艺转移至一个可替代的场所发生在大多数产品的生命周期的某些阶段，从研发、放大、生产、到上市后阶段。 Transfer of technology is defined as “a logical procedure that controls the transfer

5、 of any process together with its documentation and professional expertise between development and manufacture or between manufacture sites”. It is a systematic procedure that is followed in order to pass the documented knowledge and experience gained during development and or commercialization to a

6、n appropriate, responsible and authorized party.技术转移被定义为“控制研发方和生产方，或两个生产场所之间所有工艺文件和专业技术转移的逻辑程序”。技术转移是一个系统性的程序，遵守该程序是为了能将在研发过程中已记录的知识和经验转移给一个适当的，承担责任的经过授权的主体方。Technology transfer embodies both the transfer of documentation and the demonstrated ability of the receiving unit (RU) to effectively perform

7、 the critical elements of the transferred technology, to the satisfaction of all parties and any applicable regulatory bodies.技术转移包括文件转移和接收单位的重现能力，以使用得转移技术的关键要素得以有效实施，满足参与各方和所有适用法规的要求。 Literature searches revealed little information on the subject originating from national or regional regulatory bod

8、ies. Guidance on intracompany transfers was prepared by the International Society for Pharmaceutical Engineering (ISPE) (1).文献查阅显示来自于国家或地区药监部门关于本主题的信息非常少。ISPE（I）有一份关于跨公司转移指南。 The ever changing business strategies of pharmaceutical companies increasingly involve intra- and intercompany transfers of t

9、echnology for reasons such as the need for additional capacity, relocation of operations or consolidations and mergers. The WHO Expert Committee on Specifications for Pharmaceutical Preparations, therefore, recommended in its forty second report that WHO address this issue through preparation of WHO

10、 guidelines on this matter (2).制药企业的经营策略导致在公司间、公司内进行技术转移日益增加，原因各种各样，例如增加产能的需求、寻求新的生产场所、合并和收购。因此，WHO制剂质量标准专家委员会在WHO第42期报告中对制剂的WHO指南中阐述了对此问题的推荐。 Transfer of technology requires a documented, planned approach using trained and knowledgeable personnel working within a quality system, with documentation

11、of data covering all aspects of development, production and quality control. Usually there is a sending unit (SU), a receiving unit and the unit managing the process, which may or may not be a separate entity. For “contract manufacturing” please see good manufacturing practices (GMP) (3).技术转移需要一种记录的

12、计划方式，人员应经过培训、有知识背景，在一个质量体系下工作，数据记录应覆盖研发、生产和质量控制各方面。一般会有一个转出方(SU)，一个接收方和管理工艺的单位。管理工艺的单位可以是一个独立的主体，也可不是。关于“合同制造”，请参见GMP（3）。 For the transfer to be successful, the following general principles and requirements should be met:为使转移成功，应符合以下一般原则和要求the project plan should encompass the quality aspects of the

13、 project and be based upon the principles of quality risk management;项目计划应基于质量风险管理，对项目的质量方面起到指导作用the capabilities of the SU and at the RU should be similar, but not necessarily identical, and facilities and equipment should operate according to similar operating principles;接收单位和转出单位的产能应相似，但不是必须的，设施和

14、设备应根据相似的操作原则进行操作a comprehensive technical gap analysis between the SU and RU including technical risk assessment and potential regulatory gaps, should be performed as needed;如有需要，应对转出单位和接收单位进行综合技术差异分析，包括技术风险评估和潜在法规差异adequately trained staff should be available or should be trained at the RU:接收单位应具有经

15、过充分培训地员工，或培训其员工regulatory requirements in the countries of the SU and the RU, and in any countries where the product is intended to be supplied, should be taken into account and interpreted consistently throughout any transfer programme project; and接收单位和转出单位的所在国法规要求，以及任何该产品将要销售的国家的法规要求，均应进行考虑，并在整个转移

16、程序项目期间有一致的解释there should be effective process and product knowledge transfer.工艺和产品知识转移应有效果 Technology transfer can be considered successful if there is documented evidence that the RU can routinely reproduce the transferred product, process or method against a predefined set of specifications as agr

17、eed with the SU.如果有文件化的证据证明接收单位可以正常地再次生产出所转移的产品、工艺或方法，使用其符合与转出单位协商同意的一系列既定的规格，则可以认为技术转移已经成功。 Inthe event that the RU identifies particular problems with the process during the transfer, the RU should communicate them back to the SU to ensure continuing knowledge management.如果接收单位在转移过程中发现工艺有一些特别的问题，应

18、反馈回转出单位，以保证继续进行知识管理。 Technology transfer projects, particularly those between different companies, have legal and economic implications. If such issues, which may include intellectual property rights, royalties, pricing, conflict of interest and confidentiality, are expected to impact on open commun

19、ication of technical matters in any way, they should be addressed before and during planning and execution of the transfer.技术转移项目，是那些不同公司间转移的项目，牵涉到法律和经济方面。如果这些方面，可能会包括知识产权、版税、价格、利益和保密的冲突，将会影响到技术问题的公开交流，那么在计划和实施技术转移之前和过程中应进行说明。 Any lack of transparency may lead to ineffective transfer of technology.缺

20、乏透明度可能会导致技术转移没有效果 Some of the principles outlined in this document may also be applicable to manufacturing investigational pharmaceutical products for clinical trials as part of research and development, but this is not the main focus of this guidance and has been excluded due to the complexity of t

21、he processes.在本文件中列出的有些原则可能也适用于作为生产临床药品，作为研发的一部分，但这不是本指南主要关注点，并由于其过程太复杂因此未包括在其中。 Some of the responsibilities outlined in this document for the SU may also be considered to be part of the management unit responsibilities.在本文件件中列出的转出单位的一些职责可能也可以考虑作为管理单位的职责。2.Scope范围Note: This section specifically pro

22、vides for transfer of quality control (QC) methods where a technical agreement exists (SU manufacturer to RU manufacturer or SU manufacturer to RU QC laboratory). Where no such technical agreements exist . testing by national laboratories or testing for procurement agencies) a number of the points l

23、isted in section may not beworkable,and alternative approaches may be required.注：本部分特别提供给有技术协议存在时，质量控制方法的转移（转出生产方给接收生产单位生产方或转出单位生产方给接收单位QC化验室）。如果没有这样的技术协议存在（例如，由一个国家化验室进行检查，或由采购代理进行检测），在部分列出的一些项可能用不上，那么可能需要替代的方法。 This document gives guidance in principle and provides general recommendations on the a

24、ctivities necessary to conduct a successful intraor intersite transfer of technology as described in the Introduction to these guidelines. The intention is to address the basic considerations needed for a successful transfer in order to satisfy the regulatory authority defined for the transfer proce

25、ss.本文件给出了原则性指南，如本指南介绍中所述，提供了在工厂内、不同工厂间成功进行支持转移所需的活动建议，意在说明进行成功的技术转移所需的基本考虑，以满足在工艺转移中涉及的法规当局的要求。 The guidelines will be applied to manufacturing active pharmaceutical ingredients (APIs), manufacturing and packaging of bulk materials, manufacturing and packaging of finished pharmaceutical products (FP

26、Ps) and/or performing analytical testing.本指南适用于原料药生产活动、散装物料的生产和包装、制剂成品和/或的生产和包装、分析所用的检验方法。 The recommendations provided in these guidelines apply to all dosage forms but need to be adjusted on a case-by-case basis . by using risk management principles). Particularly close control of certain aspects

27、will be required for certain formulations such as sterile products, and metered dose aerosols. WHO guidance on manufacture of specific pharmaceutical products(4,5)will be useful in this regard.本指南中的推荐适用于所有剂型，但需要根据具体案例进行调整（例如采用风险管理原则）。对某些特殊剂型，例如无菌产品、单剂量气溶胶进行特殊控制。WHO对特殊药品的生产指南（）对此会有指导作用。 The guideline

28、s address the following areas at the SU and the RU:transfer of development and production (processing, packaging and cleaning);研发和生产转移（工艺、包装和清洁）transfer of analytical methods for quality assurance and quality control;质量保证和质量控制的分析方法转移skills assessment and training;技能评价和培训organization and management o

29、f the transfer;转移的组织和管理assessment of premises and equipment;前提和设备评价documentation; and文件，和qualification and validation.确认和验证 Because each transfer project is unique, the provision of a comprehensive set of guidelines is beyond the scope of this document.由于每个技术转移项目都是独特的，本文件并不提供一个综合性的整套指南条款。 These guid

30、elines do not provide guidance on any legal, financial or commercial considerations associated with technology transfer projects.这些指南并不提供与技术转移项目相关的任何法律、财务或商业方面的考虑。3.Glossary术语The definitions given below apply to the terms used in these guidelines.以下给出的术语定义仅限用于本指南中。They may have different meanings in

31、 other contexts.在其它上下文中可能有不同的含义。acceptance criteria可接受标准Measurable terms under which a test result will be considered acceptable.一个可以测量的标准，符合这个标准时检测结果被认为是可以接受的。active pharmaceutical ingredient (API)活性药物成份（原料药）Any substance or mixture of substances intended to be used in the manufacture of a pharmace

32、utical dosage form and that, when so used, becomes an active ingredient of that pharmaceutical dosage form. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.任何物质或混合物，用于药品制剂的生产，成为这个制剂的一种活性成份。这种物质用于产生生物学活性，或用于治愈、缓解、治疗，或防止疾病，影响人体结构和功能。Bracketing正交An experimental design to test only the extremes of, for example, dosage